Search

Displaying results 3421 - 3430 of 10000 in total
  1. Drug

    ADL 10-0101

    go.drugbank.com/drugs/DB05443
    Experimental

    Because ADL 10-0101 does not cross the blood-brain barrier and enter the brain when administered at therapeutic doses, it is expected to avoid central nervous system side effects. … ADL 10-0101 is a peripheral kappa opioid agonist analgesic product candidate.

  2. Drug

    Adrulipase alfa

    go.drugbank.com/drugs/DB15004
    Investigational

    MS-1819 is under investigation in clinical trial NCT03481803 (A Phase IIa Study With Escalating Dose of MS1819-SD).

  3. Target

    Monocarboxylate transporter 10

    go.drugbank.com/bio_entities/BE0003654
    TransporterHumans

    Sodium- and proton-independent thyroid hormones and aromatic acids transporter (PubMed:11827462, PubMed:18337592, PubMed:28754537). Mediates both uptake and efflux of 3,5,3'-triiodothyronine (T3) and 3,5,3',5'-tetraiodothyronine (T4) wit...

    Polypeptides: Monocarboxylate transporter 10Synonyms: Solute carrier family 16 member 10, MCT 10
  4. Drug

    Hetacillin

    go.drugbank.com/drugs/DB00739
    ApprovedVet approvedWithdrawn

    The name "penicillin" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. … Hetacillin has been withdrawn from the market since it has been discovered that it has no therapeutic advantage compared to non-ester derivatives like ampicillin.

    Synonyms: (2S,5R,6R)-6-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6β-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]penicillanic acid
  5. Drug

    MK-0482

    go.drugbank.com/drugs/DB17453
    Investigational

    MK-0482 is a novel humanized IgG4 monoclonal antibody targeting the immunoglobulin-like transcript (ILT) 3.

  6. Drug

    AG-24322

    go.drugbank.com/drugs/DB13035
    Investigational

    AG-024322 has been used in trials studying the treatment of Neoplasms and Lymphoma, Non-Hodgkin.

  7. Drug

    Almonertinib

    go.drugbank.com/drugs/DB16640
    ApprovedInvestigational

    [A231864] Almonertinib was also approved by the EMA on February 20, 2026.[L56068] … [A231859, A231864, A231869] Unlike other third-generation EGFR TKIs, almonertinib is a pyrimidine-based drug that forms a covalent bond to the binding site of the EGFR tyrosine kinase domain.

    Synonyms: 2-Propenamide, N-[5-[[4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxyphenyl]-, N-[5-[[4-(1-Cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxyphenyl]-2-propenamideCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inducers
  8. Drug

    Vayarin

    go.drugbank.com/drugs/DB09328
    Approved

    Approximately 60% of the users who completed 12 weeks of therapy reported subjective benefits from treatment. … Vayarin is a novel therapy for ADHD that appears to be effective in several studies [L1501, L1502, L1503].

    Categories: Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  9. Drug

    Virginiamycin M1

    go.drugbank.com/drugs/DB01669
    Experimental

    It is produced by Streptomyces graminofaciens and other bacteria.

    Synonyms: Virginiamycin M1, Virginiamycin factor M1
  10. Drug

    Lunsotogene parvec

    go.drugbank.com/drugs/DB18278
    ApprovedInvestigational

    [L56137] It acts by delivering functional copies of the human _OTOF_ gene specifically to inner hair cells via an engineered hair-cell-specific Myo15 promoter, which restores essential synaptic transmission … Lunsotogene parvec is a first-in-class dual adeno-associated virus serotype 1 vector-based gene therapy developed to address an unmet medical need for OTOF-related sensorineural hearing loss.

    Synonyms: DB-OTO